Molecular Genetic Advances in Chronic Myelogenous Leukemia
Authors: Daniel E. Epner
Journal: Annals of Internal Medicine (1990)

Editorials1 July 1990Molecular Genetic Advances in Chronic Myelogenous LeukemiaDaniel E. Epner, MD, H. Phillip Koeffler, MDDaniel E. Epner, MD, H. Phillip Koeffler, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-1-3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhile cytogenetics has been central to the study of chronic myelogenous leukemia since the discovery of the Philadelphia chromosome (Ph1) in 1960 (1, 2), the major thrust of research in recent years has been the clarification of the pathogenesis of the disease at the molecular level. Of the many variants of the Ph1 which are known to exist, all share one crucial molecular event. Abelson proto-oncogene, or ABL, is translocated from the long arm of chromosome 9 to a position adjacent to the breakpoint cluster region (BCR) gene on chromosome 22 (Figure 1, top).The ABL gene is the normal...References1. NowellHungerford PD. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497. Google Scholar2. Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [Letter]. Nature. 1973;243:290-3. CrossrefMedlineGoogle Scholar3. GoffGilboaWitte SEO. Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell. 1980;22:777-85. CrossrefMedlineGoogle Scholar4. HeisterkampGroffenStephenson NJJ. The human v-abl cellular homologue. J Mol Appl Genet. 1983;2:57-68. MedlineGoogle Scholar5. ShtivelmanLifshitzGaleCanaani EBRE. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-4. CrossrefMedlineGoogle Scholar6. ShtivelmanLifshitzGaleRoeCanaani EBRBE. Alternative splicing of RNAs transcribed from human abl gene and from the bcr-abl fused gene. Cell. 1986;47:277-84. CrossrefMedlineGoogle Scholar7. HeisterkampStephensonGroffen NJJ. Localization of the c-abl oncongene adjacent to a translocation breakpoint in CML. Nature. 1983;306:239-42. CrossrefMedlineGoogle Scholar8. GroffenStephensonHeisterkampde KleinBertramGrosveld JJNACG. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-9. CrossrefMedlineGoogle Scholar9. HeisterkampStamGroffende KleinGrosveld NKJAG. Structural organization of the bcr gene and its role in the Ph translocation. Nature. 1985;315:758-61. CrossrefMedlineGoogle Scholar10. HariharanAdams IJ. cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukemia. Embo J. 1987;6:115-9. CrossrefMedlineGoogle Scholar11. CanaaniGaleSteiner-SaltzBerrebiAghaiJanuszewicz ERDAEE. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet. 1984;1:593-5. CrossrefMedlineGoogle Scholar12. CollinsKubonishiMiyoshiGroudine SIIM. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science. 1984;225:72-4. CrossrefMedlineGoogle Scholar13. ShtivelmanGaleDreazen ERO. bcr-abl RNA in patients with chronic myelogenous leukemia. Blood. 1987;69:971-3. CrossrefMedlineGoogle Scholar14. KonopkaWatanabeWitte JSO. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37:1035-42. CrossrefMedlineGoogle Scholar15. KonopkaWatanabeSingerCollinsWitte JSJSO. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci USA. 1985;82:1810-4. CrossrefMedlineGoogle Scholar16. KloetzerKurzrockSmith WRL. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology. 1985;140:230-8. CrossrefMedlineGoogle Scholar17. UshiroCohen HS. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem. 1980;255:8363-5. CrossrefMedlineGoogle Scholar18. EkWestermarkWastesonHeldin BBAC. Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor. Nature. 1982;295:419-20. CrossrefMedlineGoogle Scholar19. NishimuraHuangDeuel JJT. Platelet-derived growth factor stimulates tyrosine specific protein kinase activity in Swiss mouse 3T3 cell membranes. Proc Natl Acad Sci USA. 1982;79:4303-7. CrossrefMedlineGoogle Scholar20. RettenmierChenRousselSherr CJMC. The product of c-fms proto-oncogene: a glycoprotein with associated tyrosine kinase activity. Science. 1985;228:320-2. CrossrefMedlineGoogle Scholar21. KasugaZickBlitheGrettazKahn MYDMC. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell free system. Nature. 1982;298:667-9. CrossrefMedlineGoogle Scholar22. RubinShiaPilch JMP. Stimulation of tyrosine-specific phosphorylation in vitro by insulin-like growth factor I. Nature. 1983;305:438-40. CrossrefMedlineGoogle Scholar23. CookMetcalfNicolaBurgessWalker WDNAF. Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell. 1985;41:677-83. CrossrefMedlineGoogle Scholar24. Mathey-PrenotNabelPalaciosBaltimore BGRD. Abelson virus abrogation of interleukin-3 dependence in a lymphoid cell line. Mol Cell Biol. 1986;6:4133-5. CrossrefMedlineGoogle Scholar25. CookdeGrothMillerMacDonaldGabathuler WSBJHR. Abelson virus transformation of an interleukin 2-dependent antigen-specific T-cell line. Mol Cell Biol. 1987;7:2631-5. CrossrefMedlineGoogle Scholar26. OliffAgrarovskyMcKinneyMurtyBauchwitz AOMVR. Friend murine leukemia virus-immortalized myeloid cells are converted into tumorigenic cell lines by Abelson leukemia virus. Proc Natl Acad Sci USA. 1985;82:3306-10. CrossrefMedlineGoogle Scholar27. WitteDasguptaBaltimore OAD. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature. 1980;283:826-31. CrossrefMedlineGoogle Scholar28. PrywesFoulkesBaltimore RJD. The minimum transforming region of c-abl is the segment encoding protein-tyrosine kinase. J Virol. 1985;54:114-22. CrossrefMedlineGoogle Scholar29. WitteGoffRosenbergBaltimore OSND. A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci USA. 1980;77:4993-7. CrossrefMedlineGoogle Scholar30. DreazenKlisakRassoolGoldmanSparkesGale OIFJRR. Do oncogenes determine clinical features in chronic myeloid leukaemia? Lancet. 1987;1:1402-5. CrossrefMedlineGoogle Scholar31. WiedemannKarhiShivji LKM. The correlation of breakpoint cluster rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood. 1988;71:349-55. CrossrefMedlineGoogle Scholar32. KurzrockBlickTalpaz RMM. Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. Ann Intern Med. 1986;105:673-9. LinkGoogle Scholar33. MorrisReeveFitzgeraldHollingsBeardHeaton CAPPMD. Genomic diversity correlates with clinical variation in Ph1-negative chronic myeloid leukaemia. Nature. 1986;320:281-3. CrossrefMedlineGoogle Scholar34. HermansHeisterkampvon Lindern ANM. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell. 1987;51:33-40. CrossrefMedlineGoogle Scholar35. ClarkMcLaughlinTimmons SJM. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988;239:775-7. CrossrefMedlineGoogle Scholar36. KoefflerGolde HD. Chronic myelogenous leukemia—new concepts. N Engl J Med. 1981;304:1201-9, 1269-74. CrossrefMedlineGoogle Scholar37. DreazenCanaaniGale OER. Molecular biology of chronic myelogenous leukemia. Semin Hematol. 1988;25:35-48. MedlineGoogle Scholar38. HeisterkampJenkinsThibodeauTestaWeinbergGroffen NRSJKJ. The bcr gene in Philadelphia chromosome positive acute lymphoblastic leukemia. Blood. 1989;73:1307-11. CrossrefMedlineGoogle Scholar39. RodenhuisSmetsSlaterBehrendtVeerman SLRHA. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia [Letter]. N Engl J Med. 1985;313:51-2. CrossrefMedlineGoogle Scholar40. EriksonGriffinar-Rushdi JCA. Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. Proc Natl Acad Sci USA. 1986;83:1807-11. CrossrefMedlineGoogle Scholar41. HoobermanCarrinoLeibowitz AJD. Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 1989;86:4259-63. CrossrefMedlineGoogle Scholar42. KurzrockShtalridRomero RMR. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature. 1987;325:631-5. CrossrefMedlineGoogle Scholar43. ClarkMcLaughlinCristChamplinWitte SJWTO. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science. 1987;235:85-8. CrossrefMedlineGoogle Scholar44. ChanKarhiRayter LKS. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature. 1987;325:635-7. CrossrefMedlineGoogle Scholar45. WalkerGanesanDhut LTS. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature. 1987;329:851-3. CrossrefMedlineGoogle Scholar46. Catovsky D. Ph1-positive acute leukemia and chronic granulocytic leukaemia: one or two diseases? Br J Haematol. 1979;42:493-8. CrossrefMedlineGoogle Scholar47. SaikiScharfFaloona RSF. Enzymatic amplification of the beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350-4. CrossrefMedlineGoogle Scholar48. DobrovicTrainorMorley AKA. Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction. Blood. 1988;72:2063-5. CrossrefMedlineGoogle Scholar49. KawasakiClarkCoyne ESM. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA. 1988;85:5698-702. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMyeloproliferative neoplasmsChronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutationsThe Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA ExpressionDoxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 ( MDR1 ) in K562 leukemic cellsAdvances in molecular diagnostics of myeloproliferative disordersEnhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cellsBCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cellsThe tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell lineBCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species–dependent DNA double-strand breaksABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-CFusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G 2 /M Phase, and Protection from ApoptosisComplementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesisBCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 ExpressionTranscription factors and translocations in lymphoid and myeloid leukemiaSignal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for LeukemogenesisInhibition of Grb2 and Crkl Proteins Results in Growth Inhibition of Philadelphia Chromosome Positive Leukemic CellsLinking analytic performance goals to medical outcomeThe management of brainstem gliomas in patients with neurofibromatosis 1Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosisSchwannomatosis: A clinical and pathologic studyLiposomal Delivery of P-Ethoxy Antisense Oligodeoxynucleotides in Chronic Myelogenous LeukemiaDiagnostic discrimination and cost effective assay strategy for leukocyte alkaline phosphataseImmunogenicity of fusion proteinsThe multistep nature of cancerPotential Therapeutic Applications of Antisense Oligodeoxynucleotides in the Treatment of Chronic Myelogenous LeukemiaDisappearance of a highly unusual clone, 46,XY,del(7)(p12),t(9;22)(q34;q11), in chronic myeloid leukemia after treatment with recombinant interferon and cytosine arabinosideChronic leukaemiasMolecular Genetics of Chronic Myelogenous LeukemiaArthur L. Hooberman, MD 1 July 1990Volume 113, Issue 1Page: 3-6KeywordsChromosomal diseasesChromosomal translocationsChronic myelogenous leukemiaCytogeneticsEcologyGenetic diseasesMemoryMolecular biologyPathogenesisResearch laboratories Issue Published: 1 July 1990 PDF downloadLoading ...